Autism Spectrum Disorder, Intellectual Disability, Phelan-McDermid Syndrome
Conditions
Keywords
Phelan-McDermid Syndrome, PMS, Genotype, Phenotype, Natural History, Mapping, 22q13 Deletion Syndrome, SHANK3, Autism Spectrum Disorder, ASD, Intellectual Disability, ID, EEG
Brief summary
The purpose of this study is to comprehensively characterize PMS using standardized medical, cognitive, and behavioral measures and to track the natural history of the syndrome using repeated longitudinal assessments. In addition, this study will be aiming to identify biomarkers using neuroimaging, including diffusion tensor imaging and identify genetic factors which contribute to diverse phenotypes in patients with PMS.
Detailed description
Phelan-McDermid syndrome (PMS) or 22q13 Deletion syndrome, caused by a loss of one copy of the SHANK3 gene, is characterized by global developmental delay/intellectual disability, motor skills deficits, delayed or absent speech, and autism spectrum disorder. The goal of this study is to understand more about the PMS phenotype and the biological pathways associated with ID and ASD in the disorder, and to establish the foundation for future clinical trials in PMS and in other ID/ASD-associated disorders that share signaling pathways with PMS. Individuals with PMS will be asked to participate in this study if they are 18 months or older with pathogenic deletions or mutations of the SHANK3 gene at time of enrollment, as well as healthy controls. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals' primary communicative language must be English. Parents and unaffected siblings may also be asked to consent to have blood drawn for analysis. The study involves 3 on site visits over 2 years. Study visits involve a physical exam, medical history questions, blood work and neuropsychological assessments. A subset of participants between the ages of 2 and 11 years old will take part in the EEG portion of the study. Individuals who have a clinically indicated MRI will have an option to provide routine clinical scans for analysis.
Interventions
None listed
Sponsors
Boston Children's Hospital
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH)
Office of Rare Diseases (ORD)
National Center for Advancing Translational Sciences (NCATS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phelan-McDermid Syndrome Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Individuals older than 18 months of age with pathogenic deletions or mutations of the SHANK3 gene * English speaking individuals
Exclusion criteria
* Has taken an investigational drug as part of another research study, within 30 days prior to study enrollment * For subjects involved in imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator * For subjects involved in EEG/ ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or over age 11 at the time of enrollment. * Unwilling or unable to comply with study procedures and assessments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in global cognitive ability at 12 months | 12 months | Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability |
| Change in adaptive behavior at 12 months | 12 months | Using Vineland Adaptive Behavior Scales to measure adaptive behavior |
| Change in language abilities at 12 months | 12 months | Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language |
| Change in motor functioning at 12 months | 12 months | Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning |
| Change in autism symptoms at 12 months | 12 months | Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism |
| Change in global cognitive ability at 24 months | 24 months | Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability |
| Change in adaptive behavior at 24 months | 24 months | Using Vineland Adaptive Behavior Scales to measure adaptive behavior |
| Change is language abilities at 24 months | 24 months | Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language |
| Change in motor functioning at 24 months | 24 months | Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning |
| Change in autism symptoms at 24 months | 24 months | Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism |
Countries
United States
Contacts
STUDY_CHAIRAlexander Kolevzon, MD
Icahn School of Medicine at Mount Sinai
Outcome results
None listed